Why current drug adherence programs fail: addressing psychological risk factors of nonadherence

被引:9
作者
Arlt, Antje D. [1 ]
Nestoriuc, Yvonne [2 ,3 ]
Rief, Winfried [1 ]
机构
[1] Philipps Univ Marburg, Clin Psychol & Psychotherapy, Marburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Psychosomat Med & Psychotherapy, Hamburg, Germany
[3] Schon Clin Hamburg Eilbek, Hamburg, Germany
关键词
cognitive impairment; compliance; depression; doctor-patient relationship; fear of side-effects; illness acceptance; nonadherence; QUALITY-OF-LIFE; HEALTH BELIEF MODEL; MEDICATION ADHERENCE; COGNITIVE IMPAIRMENT; ILLNESS ACCEPTANCE; PATIENT ADHERENCE; ENDOCRINE THERAPY; IDENTIFY PATIENTS; BREAST-CANCER; OLDER-ADULTS;
D O I
10.1097/YCO.0000000000000345
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Purpose of reviewTo provide an overview of a selection of largely neglected psychological risk factors for nonadherence, and to offer new approaches to improve medication adherence.Recent findingsCurrent adherence research and intervention programs focus on a few risk factors for nonadherence, such as complexity of the drug regimen. In addition, other important risk factors of nonadherence are neglected or insufficiently addressed. There is good evidence for the significant role of the quality of the patient-healthcare provider relationship. Other risk factors like the individual history of nonadherence, the lack of acceptance of having a treatable disorder, fear of side-effects, comorbid depression, and cognitive impairment have been broadly neglected in adherence programs, although they offer a powerful key to improve adherence-oriented interventions.SummaryCurrent research on determinants of nonadherence has focused on a few risk factors, while neglecting crucial psychological predictors of nonadherence. The personalized consideration of a multiplicity of risk factors offers a new basis for the development and evaluation of interventions to better promote adherence.
引用
收藏
页码:326 / 333
页数:8
相关论文
共 89 条
  • [1] Matching Adherence Interventions to Patient Determinants Using the Theoretical Domains Framework
    Allemann, Samuel S.
    Nieuwlaat, Robby
    van den Bemt, Bart J. f
    Hersberger, Kurt E.
    Arnet, Isabelle
    [J]. FRONTIERS IN PHARMACOLOGY, 2016, 7
  • [2] [Anonymous], 2003, Adherence to Long-Term Therapies: Evidence for action
  • [3] Is there utility in the transtheoretical model?
    Armitage, Christopher J.
    [J]. BRITISH JOURNAL OF HEALTH PSYCHOLOGY, 2009, 14 : 195 - 210
  • [4] A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease
    Articus, K.
    Baier, M.
    Tracik, F.
    Kuehn, F.
    Preuss, U. W.
    Kurz, A.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (07) : 790 - 796
  • [5] Drug therapy in the elderly: what doctors believe and patients actually do
    Barat, I
    Andreasen, F
    Damsgaard, EMS
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 51 (06) : 615 - 622
  • [6] Nonspecific medication side effects and the nocebo phenomenon
    Barsky, AJ
    Saintfort, R
    Rogers, MP
    Borus, JF
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (05): : 622 - 627
  • [7] You Can't Always Get What You Want: The Influence of Choice on Nocebo and Placebo Responding
    Bartley, Hannah
    Faasse, Kate
    Horne, Rob
    Petrie, Keith J.
    [J]. ANNALS OF BEHAVIORAL MEDICINE, 2016, 50 (03) : 445 - 451
  • [8] Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease
    Bassil, Nazem
    Thaipisuttikul, Papan
    Grossberg, George T.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (10) : 1765 - 1771
  • [9] Baudrant-Boga M., 2012, ANNALES PHARMACEUTIQUES FRANCAISES, V70, P15, DOI 10.1016/j.pharma.2011.10.003
  • [10] Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression
    Baumeister, Harald
    Hutter, Nico
    Bengel, Juergen
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (12):